Onco-Innovations Limited (CNSX: ONCO)
Health Care · Biotechnology · CA
CA$0.56
-13.85% today · -70.5% 1Y
Onco-Innovations Limited (CNSX: ONCO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $27.57M and employs 1 people.
Over the last twelve months the share price has lost 70.5%, trading between 0.50 and 1.98.
Tweenvest scores Onco-Innovations Limited across four factors: quality 28/100, value 40/100. Its strongest factor is value.
ONCO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.57M
- Revenue (TTM)
- $81.09K
- P/E
- —
- EPS
- -0.19
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CA$1.98
- 52-week low
- CA$0.50
- Avg volume (3M)
- —
- Shares outstanding
- 68.31M
- Employees
- 1
- Next earnings
- —
About Onco-Innovations Limited
Onco-Innovations Ltd. is a Canadian biotechnology company primarily focused on pioneering cancer research and developing oncology treatments. A significant offering in their portfolio is ONC010, a product specifically designed for use in cancer therapies. This enterprise was founded on September 16, 2021, and conducts its operations from its headquarters located in Calgary, Canada.
- ISIN
- CA68237C1059
- Listed since
- Nov 27, 2024
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.90 | -2.47% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Mar 19, 2025.